Novavax Company Profile (NASDAQ:NVAX)

About Novavax (NASDAQ:NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NVAX
  • CUSIP: 67000210
  • Web: www.novavax.com
Capitalization:
  • Market Cap: $296.42 million
  • Outstanding Shares: 282,595,000
Average Prices:
  • 50 Day Moving Avg: $1.18
  • 200 Day Moving Avg: $1.18
  • 52 Week Range: $0.73 - $8.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.82 million
  • Price / Sales: 17.14
  • Book Value: ($0.10) per share
  • Price / Book: -10.20
Profitability:
  • EBIDTA: ($221,620,000.00)
  • Net Margins: -1,466.36%
  • Return on Equity: -787.38%
  • Return on Assets: -56.67%
Debt:
  • Debt-to-Equity Ratio: -10.89%
  • Current Ratio: 4.57%
  • Quick Ratio: 4.57%
Misc:
  • Average Volume: 7.37 million shs.
  • Beta: 1.99
  • Short Ratio: 10.78
 
Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The firm earned $5.68 million during the quarter, compared to analysts' expectations of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The business's quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) earnings per share. View Novavax's Earnings History.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

9 equities research analysts have issued 12 month target prices for Novavax's shares. Their predictions range from $1.17 to $25.00. On average, they expect Novavax's share price to reach $5.77 in the next twelve months. View Analyst Ratings for Novavax.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (7/26/2017)
  • 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
  • 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Are investors shorting Novavax?

Novavax saw a drop in short interest in July. As of July 14th, there was short interest totalling 54,638,918 shares, a drop of 3.9% from the June 30th total of 56,851,825 shares. Based on an average daily trading volume, of 2,809,930 shares, the short-interest ratio is currently 19.4 days. Currently, 19.6% of the shares of the stock are short sold.

Who are some of Novavax's key competitors?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:

  • James Francis Young Ph.D., Independent Chairman of the Board
  • Stanley C. Erck, President, Chief Executive Officer, Director
  • Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
  • Gregory M. Glenn M.D., President, Research and Development
  • John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
  • John J. Trizzino, Senior Vice President - Commercial Operations
  • James F. Cummings, Vice President - Clinical Development and Translational Medicine
  • Rajiv I. Modi Ph.D., Director
  • Gail Koziara Boudreaux, Independent Director
  • Richard H. Douglas Ph.D., Independent Director

Who owns Novavax stock?

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include Creative Planning (0.17%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Who bought Novavax stock? Who is buying Novavax stock?

Novavax's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of Novavax stock can currently be purchased for approximately $1.02.


MarketBeat Community Rating for Novavax (NASDAQ NVAX)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $5.77 (465.81% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Chardan CapitalReiterated RatingNeutral$1.50LowView Rating Details
7/26/2017Piper Jaffray CompaniesReiterated RatingHold$1.50LowView Rating Details
7/21/2017Cantor FitzgeraldReiterated RatingHold$2.00LowView Rating Details
3/1/2017Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Novavax (NASDAQ:NVAX)
Earnings by Quarter for Novavax (NASDAQ:NVAX)
Earnings History by Quarter for Novavax (NASDAQ NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.18)($0.16)$6.17 million$5.68 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.16)($0.16)
Q3 20172($0.17)($0.16)($0.17)
Q4 20172($0.16)($0.14)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 50.04%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Michael A Mcmanus JrDirectorBuy20,000$0.97$19,400.00View SEC Filing  
5/11/2017Barclay A PhillipsCFOBuy25,000$0.84$21,000.00View SEC Filing  
5/11/2017Michael A Mcmanus JrDirectorBuy10,000$0.84$8,400.00View SEC Filing  
5/11/2017Stanley C ErckInsiderBuy50,000$0.84$42,000.00View SEC Filing  
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
Source:
DateHeadline
fool.com logoNovavax, Inc.: Buy the Dip? - Motley Fool
www.fool.com - July 28 at 6:17 AM
americanbankingnews.com logoNovavax, Inc. (NASDAQ:NVAX) Sees Significant Decline in Short Interest
www.americanbankingnews.com - July 28 at 2:21 AM
fool.com logoNovavax, Inc.: Buy the Dip?
www.fool.com - July 27 at 11:23 AM
bizjournals.com logoAnalysts on Novavax stock slide: 'The path forward did not meet expectations'
www.bizjournals.com - July 27 at 5:35 AM
finance.yahoo.com logoNovavax, Inc. (NVAX) Shares Tumble on Clinical Data; Cantor Analyst Jumps in
finance.yahoo.com - July 27 at 5:35 AM
finance.yahoo.com logoWhy Novavax, Inc Is Tanking Today
finance.yahoo.com - July 27 at 5:35 AM
finance.yahoo.com logoNovavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : July 26, 2017
finance.yahoo.com - July 27 at 5:35 AM
feeds.benzinga.com logoNovavax Update Fails To Impress; This Is Now A 'Show Me Story'
feeds.benzinga.com - July 25 at 12:32 PM
nasdaq.com logoNovavax Reports Positive Topline Data From RSV F Vaccine Phase 2 Trial
www.nasdaq.com - July 25 at 6:19 AM
finance.yahoo.com logoNovavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
finance.yahoo.com - July 25 at 6:19 AM
finance.yahoo.com logoNovavax CEO: 'We have a vaccine we like'
finance.yahoo.com - July 25 at 6:19 AM
feeds.benzinga.com logoIs There Life Left In The Novavax Clinical Program?
feeds.benzinga.com - July 24 at 5:52 PM
fool.com logoWhy Novavax Stock Spiked Today
www.fool.com - July 24 at 5:31 PM
finance.yahoo.com logoGenocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
finance.yahoo.com - July 24 at 8:45 AM
finance.yahoo.com logoShould Investors Brace for Bad News From Novavax's Looming Clinical Update?
finance.yahoo.com - July 23 at 6:39 AM
fool.com logoShould Investors Brace for Bad News From Novavax's Looming Clinical Update?
www.fool.com - July 22 at 2:38 PM
finance.yahoo.com logoReminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
finance.yahoo.com - July 22 at 7:04 AM
americanbankingnews.com logoNovavax, Inc. (NASDAQ:NVAX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - July 21 at 7:48 AM
fool.com logoHere's Why Novavax, Inc. Stock Popped Today - Motley Fool
www.fool.com - July 19 at 6:17 AM
finanznachrichten.de logoGainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH...
www.finanznachrichten.de - July 19 at 12:31 AM
streetinsider.com logoNovavax (NVAX) Plans RSV F Vaccine Update Conference Call and Webcast on July 24
www.streetinsider.com - July 19 at 12:31 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Puma Biotechnology Inc. and Novavax Inc.
finance.yahoo.com - July 19 at 12:31 AM
finance.yahoo.com logoHere's Why Novavax, Inc. Stock Popped Today
finance.yahoo.com - July 19 at 12:31 AM
finance.yahoo.com logoWhy Rite Aid, Novavax, and RH Jumped Today
finance.yahoo.com - July 19 at 12:31 AM
fool.com logoHere's Why Novavax, Inc. Stock Popped Today
www.fool.com - July 18 at 1:17 PM
seekingalpha.com logoNovavax to host RSV F vaccine update July 24; shares ahead 8% premarket
seekingalpha.com - July 18 at 7:55 AM
streetinsider.com logoNovavax (NVAX) Plans RSV F Vaccine Update Conference Call and Webcast on July 24 - StreetInsider.com
www.streetinsider.com - July 18 at 6:49 AM
finance.yahoo.com logoNovavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
finance.yahoo.com - July 18 at 6:48 AM
americanbankingnews.com logoNovavax, Inc. (NASDAQ:NVAX) Short Interest Down 11.6% in June
www.americanbankingnews.com - July 15 at 7:16 AM
finance.yahoo.com logoWhy Novavax Stock Surged Higher in June
finance.yahoo.com - July 13 at 7:27 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Novavax, Inc. (NASDAQ:NVAX) Will Announce Quarterly Sales of $5.90 Million
www.americanbankingnews.com - July 8 at 10:30 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 6 at 10:42 AM
americanbankingnews.com logoNovavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 3 at 6:52 PM
americanbankingnews.com logoNovavax, Inc. Forecasted to Post FY2018 Earnings of ($0.48) Per Share (NVAX)
www.americanbankingnews.com - June 26 at 8:16 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Expected to Post Quarterly Sales of $5.90 Million
www.americanbankingnews.com - June 14 at 12:38 PM
americanbankingnews.com logo Brokerages Expect Novavax, Inc. (NVAX) to Announce -$0.16 Earnings Per Share
www.americanbankingnews.com - June 12 at 12:14 PM
americanbankingnews.com logoShort Interest in Novavax, Inc. (NVAX) Expands By 4.8%
www.americanbankingnews.com - June 11 at 7:22 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - June 10 at 2:26 PM
americanbankingnews.com logoNovavax, Inc. (NVAX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - June 10 at 7:22 AM
streetinsider.com logoNovavax (NVAX) Says RSV F Vaccine Phase 2 Clinical Trial Data Published in Vaccine
www.streetinsider.com - June 9 at 12:48 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Kite Pharma and Novavax
finance.yahoo.com - June 8 at 9:40 AM
finance.yahoo.com logoNovavax stock surges 6% after release of full mid-stage vaccine trial results
finance.yahoo.com - June 7 at 6:44 PM
finance.yahoo.com logoThese 2 Catalysts Are Behind Novavax, Inc.'s 12% Rise in May
finance.yahoo.com - June 7 at 6:44 PM
fool.com logoThese 2 Catalysts Are Behind Novavax, Inc.'s 12% Rise in May
www.fool.com - June 7 at 11:42 AM
streetinsider.com logoNovavax (NVAX) Says RSV F Vaccine Phase 2 Clinical Trial Data Published in Vaccine - StreetInsider.com
www.streetinsider.com - June 7 at 8:22 AM
finance.yahoo.com logoNovavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
finance.yahoo.com - June 7 at 8:22 AM
americanbankingnews.com logoNovavax, Inc. (NVAX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 6 at 6:41 PM
americanbankingnews.com logoValuEngine Downgrades Novavax, Inc. (NVAX) to Strong Sell
www.americanbankingnews.com - June 3 at 11:58 PM
seekingalpha.com logoNovavax's Pipeline: Plenty Of Ammunition - Seeking Alpha
seekingalpha.com - June 1 at 7:46 PM
americanbankingnews.com logoFBR & Co Weighs in on Novavax, Inc.'s Q2 2017 Earnings (NVAX)
www.americanbankingnews.com - May 29 at 7:04 AM

Social

Chart

Novavax (NVAX) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff